Belgian biopharmaceutical firm Celyad has commenced a Phase I clinical trial (SHRINK) of its product candidate CYAD-01 (CAR-T NKG2D) for the treatment of patients with metastatic colorectal cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

CYAD-01 is a chimeric antigen receptor (CAR) T-cell therapy that is designed to use NKG2D ligands as a target.

The open-label Phase I trial will assess the safety, clinical activity and synergetic effect of various doses of CYAD-01 in combination with a standard chemotherapy called Folfox in patients carrying potentially resectable liver metastases caused by colorectal cancer.

With SHRINK being CYAD-01’s third clinical trial, the product was also investigated in the completed CM-CS1 trial and is currently being evaluated in an ongoing THINK trial.

See Also:

Celyad CEO Dr Christian Homsy said: “We are happy to start the SHRINK trial as it will allow us to evaluate the efficiency of our promising CYAD-01 therapy in combination with chemotherapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Today’s announcement, in conjunction with our ongoing THINK trial and the upcoming LINK study, reaffirms our commitment and dedication to beat cancer with a strong focus on solid tumours."

“Today’s announcement, in conjunction with our ongoing THINK trial and the upcoming LINK study, reaffirms our commitment and dedication to beat cancer with a strong focus on solid tumours.”

Comprising a dose escalation part of around 18 patients and an extension part with approximately 21 subjects, the Phase I trial will include administration of 3×108, 1×109 or 3×109 CYAD-01 at select oncology centres in the country.

Subjects will receive three successive administrations at each dose and at the specified dose, a gap of two weeks will be executed.

SHRINK is said to be based on findings from pre-clinical studies, as well on data from the THINK trial.

Image: Colon cancer with extensive mets to the liver. Photo: courtesy of James Heilman.